Science Forums Biology Forum Molecular Biology Forum Physics Chemistry Forum

Science Forums Biology Forum Molecular Biology Forum Physics Chemistry Forum (http://www.molecularstation.com/forum/)
-   Cell Biology and Cell Culture (http://www.molecularstation.com/forum/cell-biology-cell-culture/)
-   -   Molecular Therapy of Breast Cancer: Classicism Meets Modernity(announcing) (http://www.molecularstation.com/forum/cell-biology-cell-culture/66263-molecular-therapy-breast-cancer-classicism-meets-modernity-announcing.html)

scimedweb@mail.com 05-20-2009 09:19 AM

Molecular Therapy of Breast Cancer: Classicism Meets Modernity(announcing)
 
Molecular Therapy of Breast Cancer: Classicism Meets Modernity (book).

by Marc Lacroix
InTextoResearch, Baelen (Liège, Wallonia), Belgium
Nova Sciences Publishers, New York, ISBN 978-1-60741-593-0

[Only registered and activated users can see links. Click Here To Register...]

Breast cancer is the most frequently diagnosed type of cancer and a
second leading cause of cancer death in women after lung cancer.
Despite their proven efficacy, classical therapies are, however,
unable to cure metastatic breast cancer and are often associated with
significant toxicity and side-effects, due to a wide spectrum of
action. During the last years, our increasing knowledge of the
molecular pathways underlying cancer development has led to the
introduction of new drugs, of which most are directed towards very
specific targets. Rather than to be used as single agents, these
“modern” compounds could ultimately be combined with classical
molecules.
Here are described nearly 150 drugs that are currently used in routine
therapy or are in clinical trials in breast cancer patients. From the
classical tamoxifen, fluorouracil, cyclophosphamide, doxorubicin,
epirubin, docetaxel, paclitaxel…, to the more recently introduced
ixabepilone, lapatinib, vorinostat, everolimus, bevacizumab…, they
also include capecitabine, gemcitabine, trastuzumab, bevacizumab,
fulvestrant, aromatase inhibitors, cancer vaccines, inhibitors of
tumor-induced osteolysis, insulin-like growth factor-I receptor
inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors, and many
others.
This book offers an insight into current developments of breast cancer
therapy, when classicism meets modernity.

Table of Contents:
Chapter 1. Introduction

Chapter 2. Selective estrogen receptor modulators (SERMs) and down-
regulators (SERDs)

Chapter 3. Aromatase inhibitors

Chapter 4. Agents inducing ovarian suppression

Chapter 5. Antimetabolites

Chapter 6. Alkylating agents

Chapter 7. Anthracyclines

Chapter 8. Microtubule-binding agents

Chapter 9. Topoisomerase inhibitors

Chapter 10. HER family inhibitors

Chapter 11. Angiogenesis inhibitors

Chapter 12. Insulin-like growth factor-I receptor inhibitors

Chapter 13. RAS-RAF-MEK-ERK pathway inhibitors

Chapter 14. Ubiquitin-proteasome system inhibitors

Chapter 15. Histone deacetylases inhibitors

Chapter 16. Mitotic inhibitors

Chapter 17. Inhibitors of heat-shock proteins 90 and 27

Chapter 18. PI3K/AKT/mTOR pathway inhibitors

Chapter 19. Cyclooxygenase-2 inhibitors

Chapter 20. Poly(ADP-ribose) polymerase (PARP)-1 inhibitors

Chapter 21. Tumor-induced osteolysis inhibitors

Chapter 22. Vaccines and immunomodulators

Chapter 23. Varia

Index


List of drugs/compounds discussed in the book:

ABT-888, ABT-869, Ad-sig-hMUC-1/ecdCD40L vaccine, AE37 peptide/GM-CSF
vaccine, Aflibercept, AFP464, AG014699, Alendronate, Aldesleukin,
Allogeneic GM-CSF-secreting breast cancer vaccine, ALT-801, AMG 386,
AMG 479, Anastrozole, Apricoxib, ARRY-334543, AS1402, ATN-224,
Autologous dendritic cell-adenovirus p53 vaccine, AV-951, AVE1642,
AVX701, AZD0530, AZD6244, Bavituximab, Belinostat, Bevacizumab,
BGT226, BIBW 2992, BMS-754807, Bortezomib, Bosutinib, BSI-201,
Busulfan, BZL101, Capecitabine, Carboplatin, CDX-1307, Celecoxib,
Cetuximab, CHP-HER2, CHP-NY-ESO-1, Cisplatin, Cixitumumab, Clodronate,
CNF2024, CR011-vcMMAE, Cyclophosphamide, Dasatinib, Deforolimus,
Denileukin diftitox, Denosumab, Docetaxel, Doxorubicin, Entinostat,
Enzastaurin, Epirubicin, Eribulin , Erlotinib, Ertumaxomab, Etoposide,
Everolimus, Exemestane, Falimarev, Figitumumab, Fluorouracil,
Fulvestrant, Gefitinib, Gemcitabine, Goserelin, GP2 peptide/GM-CSF
vaccine, GRN163L, GSK1059615, HER2/neu (extracellular domain) peptide
vaccine, hTERT/Survivin Multi-Peptide Vaccine, Ibandronate,
Ifosfamide, Imatinib, IMP321, Inalimarev, Interleukin-12, Irinotecan,
Ispinesib, Ixabepilone, Lapatinib, Larotaxel, Letrozole, Leuprolide,
Lonafarnib, Lonaprisan, Mammaglobin-A DNA vaccine, Melphalan,
Methotrexate, MK0646, MK-0752, MLN8237, Modified vaccinia Ankara
(Bavarian Nordic)-HER2 vaccine, Neratinib, NVP-AUY922, NVP-BEZ235,
Odanacatib, OGX-427, Olaparib, OSI-906, Ovarian Cancer Peptide Mix
Immunotherapeutic Vaccine, Oxaliplatin, Paclitaxel, Panobinostat,
Patupilone, Pazopanib, PD-0332991, Pemetrexed, Pertuzumab,Picoplatin,
pNGVL3-hICD vaccine, PTC299, Ramucirumab, Recombinant fowlpox-CEA(6D)/
TRICOM vaccine, Recombinant vaccinia-CEA(6D)-TRICOM vaccine,
Retaspimycin, Rexin-G, Risedronate, Sagopilone, SCH 727965, Sialyl
Lewisª-keyhole limpet hemocyanin (KLH) conjugate vaccine, Sirolimus,
Sorafenib, Sunitinib, Tamoxifen, Telomerase: 540-548 peptide vaccine,
Temozolomide, Temsirolimus, Tesmilifene, Thiotepa, Tipifarnib,
Toremifene, Trabectedin, Trastuzumab, Trastuzumab-MCC-DM1,
Triptorelin, TTK peptide (mixed with adjuvant Montanide ISA-51),
Valproic Acid, Vandetanib, Vinflunine, Vinorelbine, Vorinostat,
WX-671, Zoledronic Acid

Bradley K. Sherman 05-20-2009 02:12 PM

Molecular Therapy of Breast Cancer: Classicism Meets Modernity(announcing)
 
In article <[Only registered and activated users can see links. Click Here To Register...]>,
<[Only registered and activated users can see links. Click Here To Register...]> wrote:

The Torture discussion belongs in talk.politics.misc. This group
is reserved for discussions of Science.

--bks



All times are GMT. The time now is 10:22 AM.

Powered by vBulletin® Version 3.8.4
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
Copyright 2005 - 2012 Molecular Station | All Rights Reserved

Page generated in 0.09352 seconds with 11 queries